U.S. Markets closed

111, Inc. (YI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.14+0.39 (+5.78%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.75
Open6.90
Bid7.07 x 900
Ask7.21 x 800
Day's Range6.90 - 7.31
52 Week Range4.46 - 8.70
Volume80,360
Avg. Volume125,087
Market Cap588.046M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-1.27
Earnings DateNov 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.97
  • 111, Inc. Announces Third Quarter 2020 Unaudited Financial Results
    PR Newswire

    111, Inc. Announces Third Quarter 2020 Unaudited Financial Results

    111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading digital healthcare platform committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the third quarter ended September 30, 2020.

  • 111 to Announce Third Quarter 2020 Unaudited Financial Results on November 19, 2020
    PR Newswire

    111 to Announce Third Quarter 2020 Unaudited Financial Results on November 19, 2020

    111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading digital healthcare platform committed to digitally connecting patients with healthcare products and services in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2020, before the U.S. market opens on Thursday, November 19, 2020.

  • 111, Inc. Teams Up with Bayer Healthcare to Explore the Vast Blue Ocean of Online Healthcare
    PR Newswire

    111, Inc. Teams Up with Bayer Healthcare to Explore the Vast Blue Ocean of Online Healthcare

    On September 24, 111, Inc. (the "Company" or "111") entered into a strategic partnership (the "Partnership") with Bayer Healthcare Co. Ltd. ("Bayer Healthcare"). The two companies will collaborate on drug commercialization initiatives in China, including the commercialization of innovative drugs and healthcare products, including for chronic disease management, as well as providing reliable and convenient resources for patient education.